TScan Therapeutics, Inc. (TCRX) Institutional Ownership

Ownership Summary

TScan Therapeutics, Inc. (NASDAQ:TCRX) is held by 60 institutional investors per 13F filings through December 2025.

• Collectively, these holders controlled 23.6% of TScan Therapeutics's outstanding shares in December 2025, down from 27.1% in September 2025.
• They increased total shares held in TScan Therapeutics by 0.01% from the prior quarter, while the number of investors in TCRX decreased 34.07% year over year.
• During the quarter, 27 of these 60 funds increased positions in TCRX, 19 reduced exposure, and 14 held steady.
• Altogether, these fund groups held 30.69Mn shares in TCRX by December 2025, up by 4.57K shares quarter on quarter, and down 11.35Mn shares year over year.
• As of December 31, 2025, Lynx1 Capital Management LP held the largest stake in TScan Therapeutics with 8.02Mn shares, accounting for 6.18% of total shares outstanding.
• Top purchasers of TCRX stock for the quarter ending December 2025 included VANGUARD CAPITAL MANAGEMENT LLC (2.15Mn), MILLENNIUM MANAGEMENT LLC (1.06Mn), JACOBS LEVY EQUITY MANAGEMENT, INC (620.2K), TWO SIGMA INVESTMENTS, LP (557.83K), BVF INC/IL (338.22K).
• Leading sellers of TScan Therapeutics shares for the quarter ending December 2025 were Aberdeen Group plc (867.22K), JANE STREET GROUP, LLC (243.86K), XTX Topco Ltd (158.28K), Goldman Sachs Group Inc (136.54K), MARSHALL WACE, LLP (101.89K).
• Business Quant data shows the 10 biggest positions in TScan Therapeutics as of December 2025 are held by Lynx1 Capital Management LP (8.02Mn), BVF INC/IL (5.56Mn), BAKER BROS. ADVISORS LP (2.78Mn), VANGUARD CAPITAL MANAGEMENT LLC (2.15Mn), BlackRock, Inc. (1.84Mn), MILLENNIUM MANAGEMENT LLC (1.46Mn), RENAISSANCE TECHNOLOGIES LLC (1.36Mn), Deer Management Co. LLC (1.25Mn), TWO SIGMA INVESTMENTS, LP (1.21Mn), Aberdeen Group plc (918.02K).